Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
It can lead to weight loss, better glycemic control, and reduced cardiometabolic risk factors
The FLOW study, an international trial of several thousand patients with kidney disease and type 2 diabetes, started in 2019, but the guideline-based recommendation for SGLT2 inhibitors as kidney-disease therapy did not emerge until 2022
Once reconstituted, it becomes susceptible to hydrolysis, oxidation, and microbial contamination making correct handling and storage critically important for patient safety
Third, taking it at a consistent time each day is easiest when you anchor it to your wake-up routine
KEY FEATURES High-purity Retatrutide research peptide 10mg lyophilised powder per vial HPLC-MS verified purity (99.79%) Manufactured in accredited laboratories Sterile, tamper-evident vial suitable for laboratory handling Fast, discreet Australia-wide shipping SPECIFICATIONS Product Name Retatrutide Peptide Grade Research Grade Quantity 10mg per vial Form Lyophilised powder Purity 99.79% (HPLC-MS tested) Appearance White/off-white lyophilised powder Storage Conditions Cool, dry environment
2 The treatment discontinuation rates due to GI adverse events were 19% in people treated with survodutide compared to 2.9% on the placebo arm
US$ 24.21
US$ 21.11
US$ 23.70
US$ 24.53
US$ 23.77
